Pozen/GlaxoSmithKline’s Trexima Gets Second FDA Approvable Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Pozen plans to pursue additional toxicity studies suggested by FDA.
You may also be interested in...
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Treximet will hit the U.S. market in mid-May, GSK says.
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Treximet will hit the U.S. market in mid-May, GSK says.
FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD
Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.